Empagliflozin in combination therapy for treating type 2 diabetes

Diabetes (type 2) - empagliflozin [ID641]: equality impact assessment - guidance review (PDF 161 KB)

Diabetes (type 2) - empagliflozin [ID641]: final appraisal determination information

Diabetes (type 2) - empagliflozin [ID641]: final appraisal determination document (PDF 494 KB)

Diabetes (type 2) - empagliflozin [ID641]: committee papers information

Diabetes (type 2) - empagliflozin [ID641]: committee papers (PDF 6.83 MB)

Diabetes (type 2) - empagliflozin [ID641]: appraisal consultation

Diabetes (type 2) - empagliflozin [ID641]: appraisal consultation document information

Diabetes (type 2) - empagliflozin [ID641]: evaluation report information

Diabetes (type 2) - empagliflozin [ID641]: evaluation report (PDF 12.5 MB)

Diabetes (type 2) empagliflozin: final scope (PDF 106 KB)

Diabetes (type 2) empagliflozin: final matrix (PDF 95 KB)

Diabetes (type 2) empagliflozin: NICE response to comments on the draft scope and provisional matrix (PDF 214 KB)

Diabetes (type 2) empagliflozin: Equality Impact Assessment (PDF 124 KB)

Diabetes (type 2) - empagliflozin: appendix B - draft scope for consultation (pre-referral) - May 2013 (PDF 81 KB)

Diabetes (type 2) - empagliflozin: appendix C - provisional matrix (pre-referral) - May 2013 (PDF 60 KB)